Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Cryoprecipitate is an allogeneic blood product prepared from human plasma. It contains factors VIII, von Willebrand factor (vWF), fibrinogen, fibronectin and factor XIII. Its use was first described in the 1960s for treatment of patients with factor VIII deficiency. It has also been used to treat patients with congenital hypofibrinogenaemia. Now, the most common use of cryoprecipitate is fibrinogen replacement in patients with acquired hypofibrinogenaemia and bleeding. Despite almost 50 years of use, evidence of efficacy is limited. This review provides an overview of the history of cryoprecipitate use, the current debates on the use of this product and future developments.

Original publication

DOI

10.1111/j.1365-3148.2012.01181.x

Type

Journal article

Journal

Transfus Med

Publication Date

10/2012

Volume

22

Pages

315 - 320

Keywords

Afibrinogenemia, Factor VIII, Factor XIII, Fibrinogen, Fibronectins, Hemorrhage, History, 20th Century, Humans, von Willebrand Factor